DelveInsight has launched a new report on Triple Negative Breast Cancer Epidemiology Forecast to 2030

DelveInsight’s ‘Triple Negative Breast Cancer Epidemiology Forecast to 2030 report delivers an in-depth understanding of the disease, historical and forecasted Triple Negative Breast Cancer (TNBC) epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Triple Negative Breast Cancer (TNBC) is defined as the heterogeneous breast cancer phenotype where the estrogen and progesterone receptor are negative, as assessed by immunohistochemistry (IHC), and there is a lack of overexpression of HER2, as assessed by immunohistochemistry (IHC), or the absence of its gene amplification, as assessed by fluorescence in situ hybridization technique. The epidemiological risk factor profiles also vary between TNBC (ER-PR-HER2-) and other breast cancers. TNBCs are frequently identified as hyper dense masses without associated calcifications. The majority of TNBCs are histologically classified as high-grade, invasive, ductal carcinomas of no special type with basal-like features. Central necrosis, pushing tumor borders, a conspicuous lymphocytic infiltrate, and fibrosis are common histologic features.

 

Click here for free sample page

Epidemiology

The Triple Negative Breast Cancer (TNBC) epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Triple Negative Breast Cancer (TNBC) epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Triple Negative Breast Cancer (TNBC) epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

 Report key facts:-

1.  A study conducted by Anders et al. titled “ER/PR negative, HER2-negative (triple-negative) breast cancer,” stated that TNBC accounted for approximately 15% of breast cancers diagnosed worldwide, which amounted to almost 200,000 cases each year. Compared with hormone receptor-positive breast cancer, TNBC is more commonly diagnosed in women younger than 40 years.

2.  A study entitled “Triple-negative breast cancer risk in women is defined by the defect of estrogen signaling: preventive and therapeutic implications” by Suba et al., stated that BRCA1/BRCA2 mutations are responsible for 3%–8% of all breast cancer cases, but 30–40% of familial cases. Among women with breast cancer, TNBC was established in 57.1% of BRCA1 mutation-positive and in 23.3% of BRCA2 mutation-positive cases, but in only 13.8% of BRCA– women.

3. Plasilova et al. conducted a study titled “Features of triple-negative breast cancer” which stated that the incidence of TNBC varied by region from 10.8% in New England to 15.8% in the east south central US (P < 0.001), as well as by race with the highest rates in African-Americans (23.7%). The incidence of TNBC also varied by histology, accounting for 76% of metaplastic cancers, but only 2% of infiltrating lobular carcinomas.

Some of key companies are working on this disease which are given below:- 

1. AstraZeneca

2. Hoffmann-La Roche

3. Merck

Name of drugs covered which are given below-

1. Lynparza

2. Tercentriq

3. Pembrolizumab

Table of contents

1. Key Insights 

2. Executive Summary of Triple Negative Breast Cancer (TNBC)

3. Triple Negative Breast Cancer (TNBC): Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this report?

• The Triple Negative Breast Cancer (TNBC) Epidemiology report will allow the user to –
• Develop business strategies by understanding the trends shaping and driving the global Triple Negative Breast Cancer (TNBC) market
• Quantify patient populations in the global Triple Negative Breast Cancer (TNBC) market to improve product design, pricing, and launch plans
• Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Triple Negative Breast Cancer (TNBC) therapeutics in each of the markets covered
• Understand the magnitude of Triple Negative Breast Cancer (TNBC) population by its epidemiology
• The Triple Negative Breast Cancer (TNBC) Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

 Related Reports:- 

1. Triple Negative Cancer- Market Insight, Epidemiology and Market Forecast -2030

2. Triple Negative Breast Cancer (TNBC)- Market Insight, Epidemiology and Market Forecast -2030

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Yash Bhardwaj
Email: Send Email
Phone: +919650213330
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/